Anal Squamous Cell Carcinoma Clinical Trial
Official title:
The Role of a 4-point Therapy Response Score With PET/CT Post Definitive Chemoradiation for Anal Squamous Cell Cancer: A Prospective Study
This study determines whether a positron emission tomography (PET)/computed tomography (CT) 4-point scoring system may predict overall survival for anal squamous cell cancer patients. A 4-point scoring system involving imaging scans may help to predict how patients with anal squamous cell cancer respond to chemoradiation therapy.
PRIMARY OBJECTIVE: I. To determine whether a PET/CT scoring system in invasive biopsy proven anal squamous cell carcinoma (SCCA) to be treated with chemoradiation with curative intent (any T any N) predicts for overall survival (OS). SECONDARY OBJECTIVES: I. To determine whether a PET/CT scoring system in invasive biopsy proven SCCA to be treated with definitive chemoradiation with curative intent predicts for progression free survival (PFS). II. To determine and validate inter-reader reliability. III. To calculate C-index to evaluate the prognostic capacity of PET/CT scores for survival. IV. To determine the association between pre-treatment PET/CT scores after treatment and OS. EXPLORATORY OBJECTIVE: I. To correlate level of standardized uptake value (SUV) pre and post therapy and its correlation with overall survival. OUTLINE: Patients undergo PET/CT at baseline and at 3 months post therapy completion. Patients' medical records are received. Patients are followed up for 5 years. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05060471 -
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
|
Phase 2 | |
Recruiting |
NCT06050707 -
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach
|
Phase 2 | |
Completed |
NCT04616196 -
Study of NKTR 255 in Combination With Cetuximab in Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01285778 -
Vectibix for the Treatment of Anal Cancer
|
Phase 2 | |
Terminated |
NCT04596033 -
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
|
Phase 1 | |
Recruiting |
NCT05374252 -
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
|
Phase 3 | |
Recruiting |
NCT05838391 -
Adaptive Radiation in Anal Cancer
|
N/A | |
Completed |
NCT01807546 -
Oral Rigosertib for Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT05328765 -
A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection
|
||
Recruiting |
NCT05438836 -
Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
|
||
Terminated |
NCT02407561 -
Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays
|
N/A | |
Completed |
NCT01115790 -
A Phase 1 Study in Participants With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT04929028 -
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02560298 -
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
|
Phase 2 | |
Withdrawn |
NCT05582031 -
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
|
Phase 2 | |
Active, not recruiting |
NCT02437851 -
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
|
Phase 2 |